Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yu know they vere at 4 cents lest november vhen they merge right.
4 cents
Folow the saml moneytrein
Yep SAML Going to Supersize alot of people
maybe now some people take me more seriously here. reading leading to dd and dd leading to smart trades.
do you have telegram ?
I folow the mony and i hold my sheres tight
I have seen paog do similiar run to .004s from the triples zeros and they is a bigg dog vith fleas.
Next saml pr and thes vil rocketship up
$lot of news items today in biotechs , buy $gold $silver
Bumply rides are ahead mick
Vhen us dolar gets further diluted and ve see gold and silver go to new highs.
Gold and silver stoks vil take over my portfolio
Good moring amerika, mick yu shuld vatch NAK.
Stok bing gong up since 70 cents
$AABB $WOGI two mining company's to radar !!!!! PROJECTIONS COURTESY
STERVC
https://investorshub.advfn.com/Asia-Broadband-Inc-AABB-14146/
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=155628791
AABB Annual Report = $5,355,473 Net Income/.12+ Valuation...
AABB Annual Report file on 04/01/2020 reflects $5,355,473 Net Income:
https://backend.otcmarkets.com/otcapi/company/financial-report/243239/content
https://investorshub.advfn.com/World-Oil-Group-Inc-WOGI-18049/
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=156774561
EXCERPT;
The company said that the plant will be able to do 50 tonnes a day in gold ore with the company owning 51% and the incoming partner will own or have a 49% ownership state for the difference. This is important because this will allow the company to capture all 100% of the Net Income for the net profits within their financials for reporting by having the 51% controlling interest in the plant. This allows for maximum growth to be applied to the company's financials.
50 Tons per day = 1,600,000 Ounces gold ore per day
1,600,000 Ounces gold ore per day x 365 days = 584,000,000 ounces of gold ore per year
$AABB $ABUS $ACCR $ACI $AEMD $AKTX $APPZ $APTY $ARCS $CAPR $COCP $IDGC $IHGP $ILST $LIQDQ $MATN $MSMY $NBRI
$OCLG $OPGN $PFWIQ $RGDXQ $RWLK $SONN $SUTI $SVTE $TFZI $TLOG $TNXP $TPTY $TRNF $VNTN $WOGI
$CAPR, $AEMD, $COCP, MRNA $PFE $BNPX Yahoo Finance's Anjalee Khemlani breaks down where pharmaceutical companies stand in the fight against COVID-19.
https://finance.yahoo.com/video/vaccine-checkup-where-pharmaceutical-companies-161644707.html
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting. In the meantime, we welcome your feedback to help us enhance the experience.
$GOLD $SILVER JUNK SILVER I AM AH BUYER !!!!!
$WHEN IS IT RIGHT !!!!! CHINA OVERSTEPPING MANY AREAS !!!!!
RE;
China menland selling usa tresuries causing usa dillar to go
down and gold and silver to go up.
Vhat is wrong vith crezy guy.
Election yeer is wrong time for fight vith china
$OCLG Bid: 0.0001 Ask: 0.0002 Last: 0.0002 Chg ($): 0.00 Vol: 188,654,424
$OCLG ONCOLOGIX TECH, INC.
PO Box 8832
Grand Rapids, MI 49518-8832
http://www.OCLGhealth.com
(616) 977-9933
info@OCLGhealth.com
DESCRIPTION
Oncologix is a diversified medical holding company that operates
and manufactures Class II medical device products,
delivers Personal Health Care Services, and sells and distributes
Durable and Home Medical Equipment.
For its clients, Oncologix provides FDA approved medical devices,
state licensed healthcare services, and medical products and technologies.
For its shareholders, Oncologix operates profitable divisions that build, maintain and nourish all shareholder value.
The Company's corporate mission is to be the best small cap medical holding company in North America.
$OCLG Snapshot Opinion https://www.barchart.com/stocks/quotes/OCLG/opinion
Yesterday
32% BUY Last Week
40% BUY Last Month
48% BUY
Snapshot Opinion is the Barchart Opinion from the prior trading session (yesterday), 1-week ago and 1-month ago.
These statistics give you a sense of the Overall Opinion trend.
China menland selling usa tresuries causing usa dillar to go down and gold and silver to go up.
Vhat is wrong vith crezy guy.
Election yeer is wrong time for fight vith china
$AABB $ABUS $ACCR $AEMD $AKTX $APPZ $APTY $ARCS $CAPR $COCP $IDGC $IHGP $ILST $LIQDQ $MATN $MSMY $NBRI
$OCLG $OPGN $PFWIQ $RGDXQ $RWLK $SONN $SUTI $SVTE $TFZI $TLOG $TNXP $TPTY $TRNF $VNTN $WOGI
$AKTX 1.9700 -0.0300 -1.50% USD 11:20AM EDT 55.152k
$CHGS Bid: 0.005 Ask: 0.0163 Last: 0.02 Chg ($): 0.0153 Vol: 20,000
$SVTE Recent Trades - Last 10 of 30
Time ET Ex Price Change Volume
10:40:12 Q 0.0042 -0.0001 14,000
10:39:47 Q 0.00425 -0.00005 37,500
10:35:49 Q 0.0043 15,000
10:35:27 Q 0.0043 150,000
10:32:05 Q 0.0043 70,000
10:30:21 Q 0.0045 0.0002 150,000
10:21:33 Q 0.0045 0.0002 50,000
10:21:33 Q 0.0046 0.0003 225,000
10:21:33 Q 0.0046 0.0003 48,865
10:21:33 Q 0.0046 0.0003 176,135
$AABB $WOGI Gold 1,899.00 +9.00(+0.48%)Silver 23.07 +0.08(+0.33%)
$AABB https://www.otcmarkets.com/stock/AABB/news/story?e&id=1632091
AABB is anticipating a three-fold increase in gold production levels in 2020 from the Company’s added operational capacity.
Gold vaults to highest since October 2012 as dollar stumbles
https://www.cnbc.com/2020/06/23/gold-markets-coronavirus-in-focus.html
$MATN& $GILD?????, 6;41 A.M. Mateon Therapeutics Appoints Dr. Anthony Maida as Chief Clinical Officer - Translational Medicine
6:41 am ET July 7, 2020 (Globe Newswire) Print
Company expands its management team to accelerate the evaluation of OT-101 for Oncology and COVID-19
[below][ OT-101, a TGF-Beta antisense drug candidate]
Mateon Therapeutics (OTC.QB: MATN), a late-stage biotechnology company developing Trabedersen (OT-101), a TGF-B inhibitor with the potential for multiple therapeutic indications including glioblastoma, pancreatic cancer, melanoma and COVID-19, appointed Anthony Maida, III, Ph.D., MA, MBA as Chief Clinical Officer - Translational Medicine for the Company.
Dr. Maida, a director of the Company since 2015, will retain his position as Board of Director. Dr. Maida is an expert in the clinical development of immuno-oncology and related products.
For close to 30 years, Dr. Maida has been involved in all aspects of commercial clinical, preclinical and scientific development of biotherapeutics including translational medicine, protocol design, FDA interactions, manufacturing process validation, and data assessment.
He has served in numerous executive and C-suite roles including Chairman, Chief Executive Officer (CEO), Chief Operating Officer (COO), Chief Scientific Officer (CSO), and Chief Financial Officer (CFO) for companies ranging from startups to public companies.
Dr. Maida has served on
multiple Boards of Directors and
Advisory Boards for public and
private companies,
hedge funds,
venture capital and pharma.
He is a member of the American Society of Clinical Oncology (ASCO),
the American Association for Cancer Research (AACR),
the Society of Neuro-Oncology (SNO),
the International Society for Biological Therapy of Cancer (iSBTC),
and the American Chemical Society (ACS).
Prior to graduate school,
Dr. Maida was Senior Controller for Lockheed Missile and Space Company,
reporting on $1.7 billion in revenue, and Vice President Finance - CFO of Lockheed DataPlan, Inc.
Dr. Maida holds a Ph.D. in Immunology (tumor immunology),
Master Degree in Toxicology,
an MBA and
two bachelor degrees (history and biology).
Dr. Maida, commented, "I look forward to driving the clinical development of OT-101 to its eventual approval as therapeutic
against COVID-19 and other indications.
The Mateon team has done a tremendous job bringing OT-101 to this stage of development and
I look forward to working closely with the entire clinical team,
our patients, our investigators, and our collaborators."
Dr. Vuong Trieu, Chief Executive Officer of Mateon said,
"We are honored that Dr. Maida has accepted the additional responsibilities within the Company.
With Dr. Maida at the helm we have further strengthened our clinical operation to deliver shareholder values across our therapeutic platforms."
About Coronavirus Disease 2019
Mateon is currently developing OT-101 as a TGF-B inhibitor against the TGF-B surge associated with COVID-19 that potentially drive the diverse clinical symptoms observed with COVID-19.
Coronavirus entry into cells is followed by suppression of cellular replication and redirection of cellular machineries to the replication of the virus. Cell cycle arrest is also centrally mediated by up-regulation of TGF-B. SARS coronavirus upregulates TGF-B via its nucleocapsid protein and papain-like protease (PLpro). SARS coronavirus PLpro activates TGF-B1 transcription both in cell-based assay and in mouse model with direct pulmonary injection. TGF-B overexpression in SARS patients lung samples also been demonstrated. Suppression of TGF-B expression by OT-101 suppressed SARS-CoV1 and SARS-CoV2 replication in the viral replication assays. This means as viral load increases there will be a proportional increase in TGF-B which in turn drives the progression of COVID-19 disease. By targeting TGF-B, OT-101 shuts off the engine behind COVID-19 allowing patients to recover without going into respiratory crisis. In fact, the administration of a soluble type II TGF-B receptor, which sequesters free TGF-B during lung injury and protected wild-type mice from pulmonary edema induced by bleomycin or Escherichia coli endotoxin.
Furthermore, mice specifically lacking bronchial epithelial TGF-b1 (epTGFbKO) displayed marked protection from influenza-induced weight loss, airway inflammation, and pathology.
Additionally, these mice exhibited a heighted antiviral state resulting in impaired viral replication in epTGFbKO mice.
Their publication succinctly described the impact of TGF-B suppression against viral infection and we would propose that TGF-beta inhibitor would result in very similar if not the same protective responses against COVID-19.
A TGF-beta inhibitor is expected to broadly impacted COVID-19 disease and we would encourage developers of TGF-beta to collaborate and build on these observations such that we can arrive at a cure for COVID-19- either as single agent or combination with Remdesivir.
About Mateon's Lead Product Candidate, OT-101
High-grade gliomas (HGG) are characterized by a T-cell exhaustion signature and pronounced T-cell hyporesponsiveness of their tumor microenvironment (TME). Transforming growth factor beta 2 (TGF- B2) has been implicated as a key contributor to the immunosuppressive landscape of the TME in HGG. OT-101, a first-in-class RNA therapeutic designed to abrogate the immunosuppressive actions of TGF- B2, is Oncotelic's lead anti-brain tumor drug candidate. OT-101 has been granted orphan designation by the FDA under the Orphan Drug Act (ODA). ODA provides for granting special status to a drug to treat a rare disease or condition upon request of a drug company. Orphan designation qualifies the sponsor of the drug for various development incentives of the ODA, including tax credits for qualified clinical testing. In a completed Phase 2 clinical study, OT-101 exhibited clinically meaningful single-agent activity and induced durable complete and partial responses in recurrent and refractory adult HGG patients, including young adults with GBM or AA.
About Mateon Therapeutics
Mateon was created by the recent reverse merger with Oncotelic which became a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB:MATN) creating an immuno-oncology company dedicated to the
development of first in class RNA therapeutics as well as small
molecule drugs against cancer.
OT-101, the lead immuno-oncology drug candidate of Mateon/Oncotelic, is a first-in-class anti-TGF beta RNA therapeutic that exhibited single agent activity in some relapsed/refractory cancer patients in clinical trial settings.
Mateon/Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on pediatric cancer patients.
Mateon has rare pediatric designation for DIPG (CA4P) and melanoma (CA4P). For more information, please visit
http://www.oncotelic.com and
http://www.mateon.com.
Mateon's Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about future plans, the progress, timing, clinical development, scope and success of future clinical trials, the reporting of clinical data for the company's product candidates and the potential use of the company's product candidates to treat various cancer indications. Each of these forward-looking statements involves risks and uncertainties and actual results may differ materially from these forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the company's annual report on Form 10-K filed with the SEC on May 20, 2020 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether as a result of new information future events, or otherwise.
Contact Information:
For Mateon Therapeutics, Inc.:
Amit Shah
ashah@oncotelic.com
https://ml.globenewswire.com/media/504ea3c8-34a5-4a06-b98b-94c5f831a368/small/mateonlogo-jpg.jpg
===============================================================
Mateon Report Positive Results for Multiple COVID-19 Drug Candidates
OT-101 and two additional candidates demonstrated viral inhibition activity against coronavirus
March 25, 2020 08:00 ET | Source: Mateon Therapeutics
AGOURA HILLS, Calif., March 25, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”) dedicated to the development of OT-101, a TGF-Beta antisense drug candidate, today provided an update on its rapid antiviral response program targeting coronaviruses, initially targeting COVID-19. OT-101 continued to show significant activity against coronaviruses and in the new testing results, two additional therapeutic oligonucleotides designed to target COVID-19 also demonstrated potent anti-viral activity. The candidates were all designed to work synergistically to avoid resistant mutations frequently seen with viral infections. OT-101 and the other candidates work by inhibiting virus binding to its target, thereby stopping the virus from replicating itself and stopping viral induced pneumonia, which often leads to patient complications. The results of the new studies came through joint efforts between Mateon and its partner, Golden Mountain Partners, LLC (GMP), which have teamed up to build an international world class program for rapid response against COVID-19 and future epidemics.
The Company has begun preparations to submit an Investigational New Drug Application (IND) to the Food and Drug Administration (FDA) for OT-101 against COVID-19 to expedite testing in COVID-19 patients.
The collaborative effort was able to manufacture and test multiple new therapeutic drug candidates within weeks from time of viral sequencing. The effort was built on the companies experience with the specific antisense backbone and its well described safety profile. OT-101 is ready to move into clinical testing in COVID-19 patients and the new candidates can be ready shortly thereafter. The anti-sense program that Mateon has developed has the potential to go from concept to clinic in months, rather than years, which is highly suitable as a rapid response to pandemics.
Dr. Vuong Trieu, President and Chief Executive Officer of Mateon stated: “We are excited about our platform for rapid response against viral epidemics and look forward to working with GMP to further expand on that platform in the US and China.”
$PASO THANK YOU
$PAOG Bid: 0.0037 Ask: 0.0039 Last: 0.0037 Chg ($): 0.0012 Vol: 115,097,866
$RGDXQ Bid: 0.0023 Ask: 0.0036 Last: 0.0036 Chg ($): 0.0013 Vol: 79,444
Yu shold add PASO to yu vatchlist
Ty mick, i heve added my. Watchlist
$YSYM [-chart]www.stockscores.com/chart.asp?TickerSymbol=VSYM&TimeRange=275&Interval=d&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=830&ChartHeight=500&LogScale=None&Band=None&avgType1=SMA&movAvg1=50&avgType2=SMA&movAvg2=100&Indicator1=RSI&Indicator2=BBW&Indicator3=AccDist&Indicator4=MACD&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen[/chart]
$CVAT Bid: 0.02 Ask: 0.0216 Last: 0.021 Chg ($): 0.0093 Vol:
$LIQDQ Bid: 0.0023 Ask: 0.0035 Last: 0.0023 Chg ($): 0.0009 Vol: 117,600
$APPZ again great find my friend. 10 click to.new web site
$APPZ. CLICK TO WEBSITE, http;//www.monsterarts.net
$APPZ on OTCMarkets web site is NEW
https://www.otcmarkets.com/stock/APPZ/profile
https://techvig.net/
$PFWIQ Petrone Worldwide (PFWIQ)
0.0004 unch (unch) 07/10/20 [OTC US]
BARCHART OPINION for Fri, Jul 10th, 2020Tutorial Alerts Watch Help
Overall Average:
48% BUY
Overall Average Signal calculated from all 13 indicators. Signal Strength is a long-term measurement of the historical strength of the Signal, while Signal Direction is a short-term (3-Day) measurement of the movement of the Signal.
$TNXP $CAPR $AMED $COCP $OPGN $pfe $bntx How the Pharma Industry Pulled Off the Pivot to COVID-19
The urgent need for tests and therapeutics has brought companies together and pushed researchers to work at breakneck speeds.
Diana Kwon
Diana Kwon
Jul 13, 2020
https://www.the-scientist.com/bio-business/how-the-pharma-industry-pulled-off-the-pivot-to-covid-19-67719
In mid-January, as cases of a mysterious illness climbed in China and began to appear in other parts of the world, Alex Zhavoronkov realized that this outbreak was becoming a major public health problem. As founder and chief executive officer of Insilico Medicine, a biotech startup based in Hong Kong—where measures to reduce the disease’s spread were already beginning to be put in place—he began to wonder what his company could do to help.
Insilico had never tackled viral diseases before; the company’s focus was on noninfectious conditions such as cancer, immunological diseases, and fibrosis. But Zhavoronkov realized that Insilico’s approach, which applies artificial intelligence (AI) for rapid novel drug discovery, could help identify potential therapeutics to fight the virus we now know as SARS-CoV-2.
Everyone, whether requested by the company priorities or just their own values, was willing to work endlessly around the clock.
—Mikael Dolsten, Pfizer
Later that month, Zhavoronkov pitched the idea to his investors and colleagues. Some were concerned that pivoting to address the novel coronavirus might be a waste of resources. “They said, ‘Look, if you do this, we can’t spend too many resources, because it’s going to go away. It’s going to be like SARS,’” Zhavoronkov recalls. During the SARS epidemic of 2002–2003, a decade before he founded Insilico, there was a surge of interest in developing treatments and vaccines—but once the virus was contained, research interest and funding streams quickly dried up. Still, enough of the people he spoke with in January were convinced that this outbreak would be more serious, and they were willing to do something to help, even if it meant recouping costs later or not at all. (See sidebar, “Ensuring Global Access,” below)
Quickly, the team got to work on repurposing their “generative chemistry platform,” which uses machine learning algorithms to design potential therapeutic molecules. Initially, the researchers focused on identifying inhibitors for a key SARS-CoV-2 protease based on the crystal structure of the enzyme. They’re now working with collaborators to synthesize these small molecules and test them against the virus in the lab.
What started out as an outbreak in China has now spread to almost every nation in the world, infected millions of people, and killed hundreds of thousands. To deal with the global threat, numerous pharmaceutical and biotech companies have adapted their pipelines to COVID-19 over the last few months. There are now close to 400 compounds being evaluated as treatments or vaccines in various preclinical studies or clinical trials and more than 700 diagnostic tests either commercially available or in development. The need for rapid solutions has brought companies together, and has pushed researchers to work at breakneck speeds—often while dealing with complications brought about by lockdowns and social distancing measures.
Companies set up pandemic pipelines
As the novel coronavirus spread around the globe, scientists at many pharmaceutical and biotech companies started to think about how to lend their expertise—either by identifying potential solutions within existing storehouses of compounds and technologies, or by applying research platforms and expertise to identify new ones. “I think everybody probably felt the urgent need to contribute,” says Dan Skovronsky, the chief scientific officer of the global pharmaceutical firm Eli Lilly. “The question that many pharmaceutical companies had, including us, was: Where are our skills, capabilities, and knowledge, and how do we best apply them?”
For companies already focusing on virus-related diagnostics, treatments, and vaccines, the switch to COVID-19 was a natural one. Pfizer, for example, had been working on vaccines for various viral and bacterial infections long before COVID-19 emerged. In March, Pfizer announced a collaboration with the German company BioNTech to develop a vaccine. Within a few months, they’d launched clinical trials of their vaccine candidates in Germany and the US.
See “COVID-19 Vaccine Frontrunners”
John Kelly, the CEO of Atomo Diagnostics, an Australian startup company that developed a rapid blood test for HIV, says that his team decided to make the shift after getting several queries from diagnostics companies about whether their platform could support a test for COVID-19. The main challenge, Kelly says, was the sheer quantity of tests that they were asking for. “The numbers that these companies were talking about were significantly beyond our existing volumes.”
We’re all asking ourselves: How do we continue to work this way, to bring this same sense of urgency and collaboration to other diseases?
—Dan Skovronsky, Eli Lilly
For other companies, the shift to COVID-19 has meant delving into a new research area. Prior to the pandemic, for example, UK-based startup biotech Owlstone’s pipeline didn’t contain any virus-focused products. The company’s diagnostic tools, which are designed to identify specific chemical compounds in people’s breath, had been geared toward cancer detection and tracking the progression of conditions such as fatty liver disease. The pandemic got the team wondering whether SARS-CoV-2, which is transmitted through respiratory droplets, could be detected with their technology. “We very quickly put together a team with a range of different academic clinical partners, along with others interested in breath research,” says Billy Boyle, Owlstone’s CEO. Within a matter of weeks, they had designed a clinical trial to test the technique and obtained the necessary approval from the UK’s Health Research Authority. That study is currently underway.
Big pharmaceutical companies have also pivoted from their usual work. Before COVID-19 hit, therapeutics for infectious diseases had not been a focus for Lilly, says Skovronsky. But he and his colleagues realized there were certain areas—the development of therapeutic antibodies, for example—where their expertise could be applied to the pandemic.
In March, Lilly joined with AbCellera, a biotech based in Vancouver, Canada. AbCellera already had a platform designed to rapidly develop medicines during pandemics, which it had established with a grant from the US Defense Advanced Research Projects Agency (DARPA). Scientists at AbCellera had obtained a blood sample from a recovered COVID-19 patient, and after running the sample through its platform—which rapidly screened for potential therapeutic antibodies using a combination of techniques, including high-throughput imaging, genomics, and AI—had identified more than 500 potential therapeutic molecules. The two companies launched a Phase 1 clinical trial of one of those antibodies in June.
“[AbCellera] told us that they had this blood and were embarking on this project and said, ‘Is this something that you guys are interested in?’” Skovronsky says. “It took us about as long as it took to read the email to make the decision.” Within about a week, the two companies had signed a deal, with the goal of starting clinical trials of a new therapeutic within four months.
People and resources adapt to new projects
The launch of new COVID-19 projects has required companies to quickly mobilize staff and resources. As a result, people involved in those projects have been working longer-than-usual hours. “The pace that we’ve had to work to fight COVID-19 is different than our normal course of work,” Skovronsky says. “I have many teams that meet every day, seven days a week.”
Mikael Dolsten, the chief scientific officer of Pfizer global R&D, says the same has been true at his company. “This was the one occasion where I felt everyone, whether requested by the company priorities or just their own values, was willing to work endlessly around the clock,” Dolsten says. “I think everyone is inspired by the call to action to have a vaccine or treatment as fast as possible.”
Many of the staff working on COVID-19 projects have been reshuffled from some of the hundreds of clinical trials that drug companies have been forced to put on hold due to the pandemic. In March, Lilly announced that the start of most new studies would be delayed and that new enrollment in ongoing studies would be halted. According to Skovronsky, many of the staff who would have been working on these trials were redeployed to work on the COVID-19 research instead.
Other companies are shuffling staff around in a similar way. Owlstone’s Boyle says his company’s stalled trials freed some employees and resources to focus on COVID-19. “We’re trying to make sure that we can still deliver on those core programs,” he adds. “But [we’re] redeploying the resources into the specific areas of the COVID problem in the near term.”
All of this has to happen alongside measures put in place to contain the virus’s spread—culling the number of staff in the lab, for example, and sending home people who could do their job virtually. “Most of our laboratories are operating at the reduced scale because of the need for social distancing,” says Dolsten. “[In the labs], we have prioritized people at work on COVID-19 and certain lifesaving new medicines that are very close to coming to the clinic.”
Companies have had to be flexible in other ways as well. Insilico usually synthesizes its compounds in Wuhan, China, for example, so when the lockdown started in that city, that part of their work was put on hold. “We just started synthesis in March,” Zhavoronkov says, adding that, as the epicenter of the pandemic has shifted, they’ve been able to restart work in Wuhan. “I think a lot of people who were using biotech services from China, when China went into lockdown, they started shifting to Europe and the US. Now it’s the other way around.”
Companies seek collaborations to accelerate research
The pandemic has brought together people from many sectors—academia, industry, and government. “One of the wonderful things that’s happened during COVID-19 is that people are working together more so than I’ve ever seen,” says Gary Wilcox, the CEO of Cocrystal Pharma, a company working with scientists at Kansas State University to develop novel antiviral compounds to treat COVID-19. “Scientists don’t always join together in one great big group for the benefit of mankind. But here, there’s been a remarkable sharing of information.”
Some of these collaborations have been formalized as larger consortia made up of multiple companies, and in some cases also funding bodies and governmental agencies. “There’s been a really interesting pivot towards embracing open innovation and a willingness to team up with partners outside of the life science ecosystem,” says Angela Radcliffe, the research and development lead for life sciences at the consulting firm Capgemini.
It is very tempting to profit from this, but I think for at least the very first steps, it is important to keep things open.
—Alex Zhavoronkov, Insilico Medicine
In March, several large pharmaceutical companies, including Eli Lilly, Novartis, Gilead, and AstraZeneca, formed a group called COVID R&D to share resources and expertise to try to accelerate the development of effective therapies and vaccines for COVID-19. That same month, the Bill & Melinda Gates Foundation, the Wellcome Trust, and Mastercard launched the COVID-19 Therapeutics Accelerator to bring researchers in industry and academia together to identify potential treatments. In April, the National Institutes of Health announced the launch of Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV), a partnership between federal researchers and 16 pharmaceutical companies to standardize the testing of therapeutics in both the lab and in clinical trials.
“There are still some companies out there who prefer to work in a more insular fashion, and that’s fine. But most of us are working together,” Skovronsky says. “I think there’s more to come, because if we have a successful drug or drug antibody, we’re going to have to work together in manufacturing it.”
Whether the accelerated rate of drug and diagnostics development or the heightened level of cooperation among different players in the business will last beyond the pandemic remains to be seen. Company leaders are thinking about how to apply the lessons being learned now to expedite the development of therapeutics for other conditions as well. “We’re all asking ourselves: How do we continue to work this way, to bring this same sense of urgency and collaboration to bear against all the other diseases—Alzheimer’s disease and cancer and autoimmune diseases and diabetes—that we work on?” Skovronsky says. “Because those patients need it also.”
Ensuring Global Access
As pharmaceutical and biotech companies rush to bring COVID-19 tests and therapeutics to the market, they have also faced increasing pressure from advocacy groups, humanitarian organizations, and investors to ensure that their products will be broadly available. Some advocates have urged governments to override patents and asked companies to commit their intellectual property to the public domain.
A handful of companies have announced plans to promote access to their products. For example, the pharmaceutical company Johnson & Johnson has promised that its effort to develop a COVID-19 vaccine with hundreds of millions of dollars from the US government’s Biomedical Advanced Research and Development Authority (BARDA) will be a nonprofit endeavor—and that if and when a product is available, the company will work with health authorities to ensure global access. Meanwhile, the pharmaceutical company Gilead Sciences, in addition to committing to donating 1.5 million doses of its experimental antiviral therapy remdesivir to the US government, signed deals with generic pharmaceutical manufacturers in India and Pakistan to distribute the drug to 127 countries that “face significant obstacles to healthcare access.”
Some companies are being more open with their intellectual property, too, at least at the early stages of research and development. Through initiatives such as the COVID-19 Therapeutics Accelerator, pharmaceutical companies including Eli Lilly have agreed to share proprietary libraries of molecular compounds for others to screen for potential COVID-19 therapeutics. These collections are shared “without worrying about [intellectual property] protection,” says Dan Skovronsky, the chief scientific officer of Eli Lilly. Insilco Medicine, although not a member of the Accelerator, has also released the molecular structures identified through its platform without patent protection, says the company’s founder and CEO, Alex Zhavoronkov. “Of course, it is very tempting to profit from this, but I think for at least the very first steps, it is important to keep things open,” he says. “Later, once we see that something works, we might be able to recover something.”
Still, many companies, including Gilead, are retaining patents on COVID-19-related products. “We want to do the right thing from a humanitarian standpoint,” says Cocrystal Pharma’s CEO Gary Wilcox. “But we also have to recognize our shareholders, and our shareholders expect us to have a return on their investment. That’s where patents come in.” In February, Cocrystal obtained an exclusive license to develop coronavirus drug candidates identified and patented by researchers at Kansas State University. Patenting is “just a part of good science,” says Pfizer Chief Scientific Officer Mikael Dolsten. “Without patents, this is not a sustainable ecosystem. Nobody would be able to afford to invest.”
$UURAF I LIKE
$HTTI Han Tang Technology, Inc.
$UURAF Rare Earth Metals up
$AABB $WOGI two mining company's to radar !!!!!
$WOGI Gold 1,885.20 +20.10(+1.08%)Silver 22.94
-0.20(-0.86%)
$WOGI World Oil Group Inc (WOGI)Overall Average:80% BUY
0.0008 -0.0001 (-11.11%) 07/22/20 [OTC US]
BARCHART OPINION for Wed, Jul 22nd, 2020Tutorial Alerts Watch Help
Overall Average:
80% BUY
Overall Average Signal calculated from all 13 indicators. Signal Strength is a long-term measurement of the historical strength of the Signal, while Signal Direction is a short-term (3-Day) measurement of the movement of the Signal.
https://www.barchart.com/stocks/quotes/WOGI/opinion
Followers
|
291
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
12211
|
Created
|
08/27/08
|
Type
|
Free
|
Moderator BEIJING BILL | |||
Assistants mick |
[chart]www.poweranime.com/images/banners/24.jpg[/chart] [chart]www.poweranime.com/images/banners/23.jpg[/chart] [chart]www.poweranime.com/images/banners/22.jpg[/chart] [chart]www.poweranime.com/images/banners/19.jpg[/chart] [chart]www.poweranime.com/images/banners/21.jpg[/chart]
http://poweranime.com/
KINGGKONGG AND THE CHINESE GENIUS TRADERS AS WE ARE OH YES SANK YOU VERY MUCH I WOULD LIKE TO OPEN DISCUSSION BOARD ON WINNING STOCKS IN AMERICAN AND IN THE UNIVERSE.
THIS BOARD IS FOR WINNER STOCKS ONLY AND IF YOU GIVE CHINESE CREW DOG STOCK THEN I WILL GIVE YOU FLEAS TO GO ALONG.
IF YOU PICK WINNER STOCKS THEN YOU MAKE MONEY AND HOPEFULLY OTHERS WHO FOLLOW STOCK OPINON WILL MAKE MONEY.
WINNER STOCKS ONLY PEASE
China Stuff. Big Ten.
China Analyst - News and Research on U.S.-Listed Chinese Stocks
http://www.cnanalyst.com/ --- scroll page.
http://www.cnanalyst.com/dailystocks/
http://www.cnanalyst.com/daily/ --- news items;
http://www.cnanalyst.com/analystactions/
http://www.cnanalyst.com/peg/
http://www.cnanalyst.com/ownership/
http://www.cnanalyst.com/shortinterest/
http://www.cnanalyst.com/solar/
http://www.cnanalyst.com/2010/02/top-10-most-efficient-otc-stocks-glbt-tuyu-junp-vtsi-cnoa-egmi-sslty-cyln-apdn-esyg-feb-24-2010.html
GOOD LUCK TO ALL WHO FOLLOW CHINA POWER!
THIS IS KIMCHI MY SUPER TRANIEE WHO SURVIVE CLASS OF 24. HE TAKE GOOD ORDERS. HAHEHA
AND MYSELF NED NO NTRODUCTON AS I AM FAMOUS FOR MANY ACOMPLISHMENTS SO SING UP BELOW AND REGISTER AND YOU TOO WIL BECOME SUCESFUL AND BEGIN TO MAKE MORE MONEY THAN UNCLE SAM AND UNCLE BUCK COMBINED.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |